PMCB News and Press, PharmaCyte Biotech Inc. From 03/16/22

PharmaCyte Biotech press release (NASDAQ:PMCB): Q3 cash on hand of approximately $87M as of January 31, 2022. For further details see: PharmaCyte Biotech reports Q3 results

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today the financial and operational results for its third qu...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced the results of an additional, more finely detailed, analys...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today provided an update on PharmaCyte’s activities to lift the U.S...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it will be featured as a presenting company at the H....

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that the empty capsule material that makes up PharmaCyte&#...

PharmaCyte Biotech (PMCB +1.9%) said it successfully completed a 36-month stability study of the cells from its Master Cell Bank (MCB), as part of its efforts to get a clinical hold lifted by the U.S. Food and Drug Administration (FDA). This stability study is one of the items that the F...

PharmaCyte Biotech, Inc. (NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , today announced that it has successfully completed a 36-month stability st...

PharmaCyte Biotech (NASDAQ:PMCB): FQ2 cash on hand of approximately $87 million as of October 31, 2021. Press Release For further details see: PharmaCyte Biotech reports FQ2 results

PharmaCyte Biotech, Inc. NASDAQ: PMCB), a biotechnology company focused on developing cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box ® , announced today the financial results for its second quarter ended Octo...